中国异基因造血干细胞移植治疗血液系统疾病专家共识（Ⅲ）——急性移植物抗宿主病（2020年版）

2020-07-20 中华医学会血液学分会中华血液学杂志.2020.41(7):529-536.

异基因造血干细胞移植（allo-HSCT）是治疗多种血液系统疾病的有效方法，单倍型造血干细胞移植（haplo-HSCT）的成功使我国造血干细胞移植病例数量快速增长。据中国造血干细胞移植登记组报告，20

中文标题：

发布机构：

中华医学会血液学分会

发布日期：

2020-07-20

简要介绍：

异基因造血干细胞移植（allo-HSCT）是治疗多种血液系统疾病的有效方法，单倍型造血干细胞移植（haplo-HSCT）的成功使我国造血干细胞移植病例数量快速增长。据中国造血干细胞移植登记组报告，2019 年我国140 家单位实施allo-HSCT 近万例，其中haplo-HSCT占60％。尽管allo-HSCT的疗效不断改善，移植物抗宿主病（GVHD）仍然是主要的合并症和死亡原因。目前急性GVHD的国际指南中的证据多来自HLA相合同胞供者（简称同胞相合）移植和非血缘供者移植，各种指南的推荐存在差异，推荐的疗效评判标准和严重程度分度标准也不尽相同。与国外allo-HSCT 以HLA 相合移植和非血缘供者移植为主的模式明显不同，我国haplo-HSCT占第一位。鉴于我国的移植现状，加之各移植单位规模差别较大，急性GVHD的处理经验难免存在差别，所以有必要制定中国的专家共识。本共识在国际指南基础上纳入了中国医师在该领域的主要研究成果和临床经验，旨在形成适合中国情况的诊疗规范，为各移植单位提供指导性意见，并为移植中心之间的交流和合作奠定良好基础。共识由22位本领域的权威专家参与讨论制定。

下载附件：

点击下载

(因为版权问题，不支持下载)

评论区 (20)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1195446, encodeId=7330119544634, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e842632905, createdName=492892895, createdTime=Sun Feb 20 21:59:19 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183836, encodeId=417a1183836ee, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=655a2287800, createdName=121dcc47m45(暂无昵称), createdTime=Thu Jan 13 11:10:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083451, encodeId=f3e41083451f0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08bc5311998, createdName=amma229, createdTime=Thu Dec 23 08:52:38 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056555, encodeId=2a8c105655530, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:34:37 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056349, encodeId=139810563496b, content=有慢性GVHD指南哪, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55691851131, createdName=ms4958246494604504, createdTime=Thu Sep 30 07:05:31 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2022-02-20 492892895

学习

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1195446, encodeId=7330119544634, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e842632905, createdName=492892895, createdTime=Sun Feb 20 21:59:19 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183836, encodeId=417a1183836ee, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=655a2287800, createdName=121dcc47m45(暂无昵称), createdTime=Thu Jan 13 11:10:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083451, encodeId=f3e41083451f0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08bc5311998, createdName=amma229, createdTime=Thu Dec 23 08:52:38 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056555, encodeId=2a8c105655530, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:34:37 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056349, encodeId=139810563496b, content=有慢性GVHD指南哪, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55691851131, createdName=ms4958246494604504, createdTime=Thu Sep 30 07:05:31 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2022-01-13 121dcc47m45(暂无昵称)

感谢分享

89 0
[GetPortalCommentsPageByObjectIdResponse(id=1195446, encodeId=7330119544634, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e842632905, createdName=492892895, createdTime=Sun Feb 20 21:59:19 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183836, encodeId=417a1183836ee, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=655a2287800, createdName=121dcc47m45(暂无昵称), createdTime=Thu Jan 13 11:10:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083451, encodeId=f3e41083451f0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08bc5311998, createdName=amma229, createdTime=Thu Dec 23 08:52:38 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056555, encodeId=2a8c105655530, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:34:37 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056349, encodeId=139810563496b, content=有慢性GVHD指南哪, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55691851131, createdName=ms4958246494604504, createdTime=Thu Sep 30 07:05:31 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-12-23 amma229

学习学习

101 0
[GetPortalCommentsPageByObjectIdResponse(id=1195446, encodeId=7330119544634, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e842632905, createdName=492892895, createdTime=Sun Feb 20 21:59:19 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183836, encodeId=417a1183836ee, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=655a2287800, createdName=121dcc47m45(暂无昵称), createdTime=Thu Jan 13 11:10:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083451, encodeId=f3e41083451f0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08bc5311998, createdName=amma229, createdTime=Thu Dec 23 08:52:38 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056555, encodeId=2a8c105655530, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:34:37 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056349, encodeId=139810563496b, content=有慢性GVHD指南哪, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55691851131, createdName=ms4958246494604504, createdTime=Thu Sep 30 07:05:31 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-09-30 13f0c37dm61暂无昵称

值得学习

95 0
[GetPortalCommentsPageByObjectIdResponse(id=1195446, encodeId=7330119544634, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e842632905, createdName=492892895, createdTime=Sun Feb 20 21:59:19 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183836, encodeId=417a1183836ee, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=655a2287800, createdName=121dcc47m45(暂无昵称), createdTime=Thu Jan 13 11:10:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083451, encodeId=f3e41083451f0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08bc5311998, createdName=amma229, createdTime=Thu Dec 23 08:52:38 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056555, encodeId=2a8c105655530, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:34:37 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056349, encodeId=139810563496b, content=有慢性GVHD指南哪, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55691851131, createdName=ms4958246494604504, createdTime=Thu Sep 30 07:05:31 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-09-30 ms4958246494604504

有慢性GVHD指南哪

93 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

中国异基因造血干细胞移植治疗血液系统疾病专家共识（Ⅲ）——急性移植物抗宿主病（2020年版）

相关指南

拓展阅读

科室

工具

服务